FindTrial
Sign In

RANDOMIZED STUDY OF PHASE III WITH RADIOTHERAPY IN PATIENTS MASTECTOMIZED BY BREAST CANCER OF CLINICAL STAGE II, WITH ONE TO THREE POSITIVE GANGLES

RANDOMIZED STUDY OF PHASE III WITH RADIOTHERAPY IN PATIENTS MASTECTOMIZED BY BREAST CANCER OF CLINICAL STAGE II, WITH ONE TO THREE POSITIVE GANGLES

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-076-03
Enrollment
14
Registered
2004-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

radiotherapy Type of group
Radiotherapy will be administered using modern equipment with sophisticated planning techniques that will minimize the side effects related to it including the 5% excess risk of lymphoedema,

Sponsors

EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients should be women with breast adenocarcinoma, histologically confirmed, with a primary tumor of <5 cm and 1-3 positive axillary lymph nodes. Patients with positive lymph nodes only by cytokeratin staining and negative with hematoxylin-eosin are not eligible. Patients must not have received Trastuzumab previously.

Exclusion criteria

Exclusion criteria: underage pregnant women

Design outcomes

Primary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Secondary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Countries

Peru, United States

Outcome results

None listed

Source: REPEC (via WHO ICTRP)